DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Chlorphen Mal Pseudoeph (Chlorpheniramine Maleate / Pseudoephedrine Hydrochloride) - Summary

 
 



SUMMARY

Chlorphen Mal/Pseudoeph HCl 0.8/9 mg Drops is an antihistaminic and decongestant drop for oral administration.

Chlorphen Mal/Pseudoeph HCl 0.8/9 mg Drops is indicated for symptomatic relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

See all Chlorphen Mal Pseudoeph indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Chlorphen Mal Pseudoeph (Chlorpheniramine / Pseudoephedrine)

Medical News Today: Peanut allergy could be cured with probiotics
Source: Featured Health News from Medical News Today [2017.08.18]
The vast majority of children in a large clinical trial continued to tolerate peanuts for 4 years after it had ended, new research shows.

Peanut allergy could be cured with probiotics
Source: Allergy News From Medical News Today [2017.08.18]
The vast majority of children in a large clinical trial continued to tolerate peanuts for 4 years after it had ended, new research shows.

Allergy wheezing: Causes, diagnosis, and treatment
Source: Allergy News From Medical News Today [2017.08.16]
What is allergy wheezing? In this article, learn how allergies may cause wheezing and what the symptoms may be. How is allergy wheezing treated?

Common allergy drugs may prevent blood clots
Source: Allergy News From Medical News Today [2017.08.04]
New research in mice suggests that common allergy drugs may offer a bleeding risk-free alternative to existing anti-clotting medication.

Alpha-gal allergy: What you need to know
Source: Allergy News From Medical News Today [2017.07.29]
What is an alpha-gal allergy and what are the causes of it? Learn about the symptoms, how it is diagnosed, how it can be treated, and prevention methods.

more news >>

Clinical Trials Related to Chlorphen Mal Pseudoeph (Chlorpheniramine / Pseudoephedrine)

Study of AHIST in Seasonal Allergic Rhinitis Patients [Withdrawn]
Objectives: A) To gather pharmacodynamic measurements and assess blood levels of the active ingredients in AHIST over the dosage interval period of 12 hours. Hypothesis: Hysteresis curves plotting each active ingredient's blood levels over a 12-hour dosage interval will substantiate S5 Symptom Diary scores (IE: evidentiary therapeutic window data); B) To report subjective scores by subjects rating the efficacy of a single dose AHIST in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over a 12-hour dosage interval. Hypothesis: Greater than 66% of subjects will document clinically significant relief over a 12-hour period from one dose of AHIST; C) Report any side effects or adverse drug reactions and rate the severity of any incidence. Hypothesis: Not more than one patient will have an adverse event significant enough to warrant withdrawal; side effects will be mild with the most frequently reported side effect occurring in less than 10% of patients—drowsiness.

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fed conditions.

Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents [Completed]

Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fasting conditions.

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study [Active, not recruiting]
This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p < 0. 05.

more trials >>


Page last updated: 2017-08-18

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017